Invea Therapeutics Strengthens Leadership with Appointment of Dr. Stephen Doberstein, Veteran Biotech Executive, to Its Board of Directors GUILFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc. (Invea), a leading biotechnology company developing an artificial intelligence (AI), GenAI, and machine learning (ML)...

Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...

Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors - Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to advance additional programs, including a...

Invea Therapeutics Announces Poster Presentations at Keystone Symposia Gut-Brain Axis and Digestive Disease Week (DDW2022) GUILFORD, Conn., March 17, 2022 (GLOBE NEWSWIRE) -- Invea Therapeutics, Inc., a global leader in applying Artificial Intelligence (AI) and Machine Learning (ML) to transform drug discovery and...